Autism Spectrum Disorders Clinical Trial
Official title:
Osteopathic Manual Medicine Treatment in Autism, A Pilot Study
The purpose of this study is to determine how osteopathic manual medicine (OMM) will affect core autism features including social and communication deficits. The investigators believe that OMM approaches can positively influence some features associated with Autism/Autism Spectrum Disorder (ASD).
Autism is a complex neuro-developmental disorder of early childhood onset characterized by impairments in the core triad of social interaction, repetitive-stereotypes behaviors, and verbal/nonverbal communication. This major public health concern exerts an enormous toll on the quality of life of affected individuals, families, and society. Though there are medications available for use in managing autism associated behaviors, including aggression, self-injury and hyperactivity, there are no medical treatments of proven benefit in treating core autistic features such as social and communication deficits. Complementary and alternative medical treatments(CAM) are commonly used by individuals with a wide variety of medical diseases including autism despite little evidence-based support for their efficacy. Recent surveys reveal the prevalence of CAM use in children with autism to be between 30% and 95%. Osteopathic Manual Medicine (OMM) is one of the most well studied CAM treatments, achieving widening acceptance with increasing evidence of safety and efficacy, as an adjunct in the treatment of a number of conditions. OMM appears to be a safe treatment modality in the pediatric population when administered by physicians with expertise in OMM. At a physiologic level, OMM has been proposed to elicit some of its therapeutic and biomechanical effects through an ability to mobilize body fluids, increase removal of metabolic waste, and boost immune function. OMM has been shown to have favorable effects on neuro-endocrine and immunologic function. As theories of autism pathogenesis often revolve around immune dysregulation including lowered IgA levels, and accumulation of metabolic and xenobiotic agents, there are theoretical mechanisms through which OMM can exert therapeutic effects. In practice, OMM has been shown to improve sensory and motor performance with neurological problems, including autism. Additionally, studies of manual medicine techniques similar in principle to OMM, including Qigong massage and Tuina, have yielded favorable outcomes on a number of core autistic features including social, language, sensory, cognition and self-care domains as measured by the Autism Behavior Checklist (ABC) and Functional Independence Measures for Children(WeeFIM). 30 subjects will be randomized to receive OMM or sham treatments. Standardized assessment tools for autism symptom severity (ABC and WeeFIM) will be administered pre- and post-study to compare treatment efficacy between arm. Saliva samples will be collected pre- and post-treatment sessions to evaluate biochemical response and to catalog genetic markers that could provide insight into subsets exhibiting differential response. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02625116 -
ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
|
||
Not yet recruiting |
NCT06381856 -
Improving Participation of Autistic Children and Adolescents in the Habilitation Process
|
||
Recruiting |
NCT02280746 -
Gluten for Autism Spectrum Disorders
|
N/A | |
Completed |
NCT01945957 -
Brain Imaging of Intranasal Oxytocin Treatment in Autism
|
Phase 1 | |
Completed |
NCT01661855 -
A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD
|
Phase 2 | |
Completed |
NCT01780090 -
Handheld Technology for Speech Development in Students With Autism
|
N/A | |
Completed |
NCT01592747 -
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
|
Phase 2 | |
Completed |
NCT01694667 -
Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
|
Phase 2 | |
Completed |
NCT01691066 -
Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder
|
N/A | |
Active, not recruiting |
NCT01417026 -
Intranasal Oxytocin and Learning in Autism
|
Phase 2 | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Completed |
NCT01695200 -
Omega-3 Fatty Acids in Autism Spectrum Disorders
|
Phase 4 | |
Completed |
NCT02300597 -
Internet-based Support for Young People With ADHD and Autism - a Controlled Study
|
N/A | |
Completed |
NCT01675414 -
Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
Not yet recruiting |
NCT00695812 -
The Development of Younger Siblings of Children With Autism Now at 10 Years of Age
|
N/A | |
Recruiting |
NCT05910502 -
Project AFECT (Autism Family Empowerment Coaching and Training Program)
|
N/A | |
Completed |
NCT02081027 -
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
|
Early Phase 1 | |
Completed |
NCT02797379 -
The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders
|
N/A | |
Terminated |
NCT01730079 -
Near Infrared Spectroscopy in Children With Autism and ADHD
|
||
Completed |
NCT01603225 -
Transcranial Direct Current Stimulation and Autism
|